[Federal Register Volume 77, Number 30 (Tuesday, February 14, 2012)]
[Notices]
[Pages 8270-8271]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-3440]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of a meeting of the 
Recombinant DNA Advisory Committee.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: Recombinant DNA Advisory Committee.
    Date: March 7-8, 2012.
    Time: March 7, 2012, 3:30 p.m. to 5:30 p.m.
    Agenda: The NIH Recombinant DNA Advisory Committee (RAC) will 
review and discuss selected human gene transfer protocols and 
related data management activities. Please check the meeting agenda 
at

[[Page 8271]]

OBA Meetings Page (available at the following URL: http://oba.od.nih.gov/rdna_rac/rac_meetings.html) for more information.
    Place: National Institutes of Health, Building 31C, 9000 
Rockville Pike, Conference Room 6 & 8, Bethesda, MD 20892.
    Time: March 8, 2012, 8:30 a.m. to 3:00 p.m.
    Agenda: The NIH Recombinant DNA Advisory Committee (RAC) will 
review and discuss selected human gene transfer protocols and 
related data management activities. Please check the meeting agenda 
at OBA Meetings Page (available at the following URL: http://oba.od.nih.gov/rdna_rac/rac_meetings.html) for more information.
    Place: National Institutes of Health, Building 31C, 9000 
Rockville Pike, Conference Room 6 & 8, Bethesda, MD 20892.
    Contact Person: Chezelle George, Office of Biotechnology 
Activities, Office of Science Policy/OD, National Institutes of 
Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892, 301-496-
9838, <a href="/cdn-cgi/l/email-protection#1a7d7f75687d7f795a757e34747372347d756c"><span class="__cf_email__" data-cfemail="dcbbb9b3aebbb9bf9cb3b8f2b2b5b4f2bbb3aa">[email protected]</span></a>.

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    OBA will be piloting a new system to offer those members of the 
public viewing the meeting via webcast (see link on OBA Meetings 
Page) the opportunity to submit comments to be read during the 
scheduled public comment periods. Individuals wishing to submit 
comments should use the comment form, which will accommodate 
comments up to 1500 characters, and will be available on the OBA 
Meetings Page during the meeting. Please submit your comment prior 
to the start of the public comment period. Please limit your comment 
to a statement that can be read in one to two minutes. Please 
include your name and affiliation with your comment.
    OBA will read comments into the record during the public comment 
periods that are specified on the agenda. Please note, while every 
effort is made to keep the meeting discussions to the times stated 
on the agenda, it is not unusual for the meeting to run ahead or 
behind schedule due to changes in the time needed to review a 
protocol. It is advisable to monitor the webcast to determine when 
public comments will be read. Comments submitted electronically will 
follow any comments by individuals attending the meeting in person. 
Comments will be read in the order received and your name and 
affiliation will be read with the comment. Please note OBA may not 
be able to read every comment received in the time allotted for 
public comment. Comments not read will become part of the public 
record.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.
    Information is also available on the Institute's/Center's home 
page: http://oba.od.nih.gov/rdna/rdna.html, where an agenda and any 
additional information for the meeting will be posted when 
available.
    OMB's ``Mandatory Information Requirements for Federal 
Assistance Program Announcements'' (45 FR 39592, June 11, 1980) 
requires a statement concerning the official government programs 
contained in the Catalog of Federal Domestic Assistance. Normally 
NIH lists in its announcements the number and title of affected 
individual programs for the guidance of the public. Because the 
guidance in this notice covers virtually every NIH and Federal 
research program in which DNA recombinant molecule techniques could 
be used, it has been determined not to be cost effective or in the 
public interest to attempt to list these programs. Such a list would 
likely require several additional pages. In addition, NIH could not 
be certain that every Federal program would be included as many 
Federal agencies, as well as private organizations, both national 
and international, have elected to follow the NIH Guidelines. In 
lieu of the individual program listing, NIH invites readers to 
direct questions to the information address above about whether 
individual programs listed in the Catalog of Federal Domestic 
Assistance are affected.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.22, Clinical Research Loan 
Repayment Program for Individuals from Disadvantaged Backgrounds; 
93.232, Loan Repayment Program for Research Generally; 93.39, 
Academic Research Enhancement Award; 93.936, NIH Acquired 
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, 
Undergraduate Scholarship Program for Individuals from Disadvantaged 
Backgrounds, National Institutes of Health, HHS)

    Dated: February 7, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-3440 Filed 2-13-12; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>